Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO Sells $1,280,700.00 in Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) CEO John E. Kao sold 90,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $14.23, for a total transaction of $1,280,700.00. Following the completion of the transaction, the chief executive officer now owns 2,183,100 shares of the company’s stock, valued at approximately $31,065,513. The trade was a 3.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Alignment Healthcare Trading Down 4.5 %

ALHC stock opened at $13.87 on Friday. The firm has a fifty day moving average price of $12.91 and a 200 day moving average price of $11.55. Alignment Healthcare, Inc. has a fifty-two week low of $4.46 and a fifty-two week high of $15.82. The firm has a market cap of $2.66 billion, a PE ratio of -18.01 and a beta of 1.50. The company has a debt-to-equity ratio of 1.82, a quick ratio of 1.60 and a current ratio of 1.60.

Analysts Set New Price Targets

Several brokerages recently weighed in on ALHC. Stifel Nicolaus upped their target price on shares of Alignment Healthcare from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, January 14th. UBS Group increased their target price on Alignment Healthcare from $9.00 to $12.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Barclays boosted their price target on Alignment Healthcare from $7.00 to $8.00 and gave the stock an “underweight” rating in a report on Wednesday, October 30th. Finally, Stephens reaffirmed an “overweight” rating and set a $17.00 price objective on shares of Alignment Healthcare in a report on Thursday, January 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.88.

Institutional Trading of Alignment Healthcare

Large investors have recently made changes to their positions in the business. R Squared Ltd purchased a new position in Alignment Healthcare in the fourth quarter worth about $55,000. nVerses Capital LLC purchased a new position in shares of Alignment Healthcare in the 3rd quarter worth approximately $95,000. Ballentine Partners LLC purchased a new position in shares of Alignment Healthcare in the 4th quarter worth approximately $121,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Alignment Healthcare during the 3rd quarter valued at approximately $131,000. Finally, Aigen Investment Management LP purchased a new stake in Alignment Healthcare during the 4th quarter valued at $129,000. 86.19% of the stock is currently owned by institutional investors.

About Alignment Healthcare

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform for seniors in the United States. It provides customized health care designed to meet the needs of a diverse array of seniors through its Medicare advantage plans. The company was founded in 2013 and is based in Orange, California.